LTZ Therapeutics, a dynamic biotech company with operations in Redwood City, California, and Shenzhen, China, has successfully raised over $10 million in pre-A+ financing. Qiming Venture Partners led the funding round, with participation from notable investors including Shunwei Capital, Lihehongxin Venture Capital Partnership, and K2 Venture Partners.
Since its inception in 2022, LTZ Therapeutics has amassed a total funding of approximately $30 million, demonstrating the significant support and confidence in its immunotherapy-focused approach. The newly secured funds will be instrumental in further establishing LTZ’s platform and pipeline, as well as expanding its global operations team.
Under the leadership of Co-Founder and CEO Dr. Robert Li, LTZ Therapeutics is dedicated to pioneering novel therapies that address unmet clinical needs in patients with cancer and other diseases. With a robust presence in both Redwood City and Shenzhen, along with a talented team in Heidelberg, Germany, LTZ leverages reverse translational science and the emerging biology of the tumor microenvironment to develop immunotherapies that overcome resistance and enhance anti-tumor immunity.
At the core of LTZ’s focus is harnessing the power of innate immunity, including macrophages, and eliminating immunosuppression factors like T regulatory cells and cancer-associated fibroblasts. These areas hold immense potential for creating innovative and effective therapies. LTZ is actively developing its own groundbreaking Innate Engager Platform, which activates macrophages and natural killer (NK) cells to directly combat tumors and suppress immune evasion, thereby stimulating inflammation within the tumor microenvironment. This, in turn, promotes activated adaptive immunity and establishes long-term memory against the disease.
To further bolster its scientific expertise, LTZ Therapeutics has expanded its scientific board, welcoming esteemed members Dr. Lillian L Siu, Dr. Stephen Beers, and Dr. Hiroyoshi Nishikawa. They join the accomplished lineup of Dr. Sarah Hymowitz, Dr. Greg Cosma, and Dr. Lukas Amler, collectively contributing to LTZ’s pioneering efforts in the field of immunotherapy.
